FDA Dismisses List Of “Grandfathered” Ingredients In Pyridoxamine Decision
This article was originally published in The Tan Sheet
Companies determining whether a substance is a new dietary ingredient cannot rely on industry-developed lists of "grandfathered" ingredients believed to be marketed prior to the Dietary Supplement Health and Education Act, FDA says in response to a citizen petition
You may also be interested in...
ViGuard Health says in a petition that with two IND programs for studies of pyridoxamine's potential therapeutic use formally withdrawn, FDA should rescind its 2009 decision that it did not qualify as a dietary ingredient.
International Trade Commission won't investigate Amarin's complaint that some dietary supplements containing omega-3 formulations similar to icosapent ethyl in its Vascepa are actually drugs and should be blocked from import into US, likely discouraging others from this novel approach.
Pyridoxamine's presence in many common foods makes it exempt from 75-day premarket notification, the Council for Responsible Nutrition maintains in comments supporting the ingredient's status as a dietary supplement